Kisspeptin-10

What is kisspeptin-10?

Kisspeptin-10 is a ten-amino-acid peptide, the shortest active form of kisspeptin. Kisspeptin is a natural hormone made in the brain that switches on the reproductive system. The gene that encodes it, KISS1, was discovered in 1996 by researchers in Hershey, Pennsylvania, who named it after the town's famous chocolate.

At first the gene was studied as a suppressor of cancer spread, which is why one of its products is called metastin.¹ In 2001 kisspeptins were identified as the natural partners of a receptor called GPR54. In 2003, two research groups found that people with broken copies of that receptor never go through puberty, which revealed kisspeptin's central role in reproduction.¹ Kisspeptin-10 is not an approved drug. It is studied in fertility research and marketed online and by some clinics for testosterone support and libido.

How kisspeptin-10 works

The reproductive system runs on a chain of signals. The hypothalamus releases gonadotropin-releasing hormone (GnRH). GnRH tells the pituitary to release LH and FSH. Those hormones tell the testes or ovaries to make sex hormones and sperm or eggs. Kisspeptin sits at the top of that chain. It is the signal that tells GnRH neurons to fire.

Because kisspeptin works upstream, it uses the body's own control system rather than replacing a hormone further down. The hope is that this produces a more natural hormone pattern than giving GnRH, LH or testosterone directly.

In more precise terms, kisspeptin-10 is an agonist at KISS1R (also called GPR54), a G protein-coupled receptor on hypothalamic GnRH neurons. The kisspeptin system acts as a gatekeeper of GnRH neurons. It helps switch them on at puberty and helps relay feedback from sex steroids and, probably, metabolic signals.¹ In monkeys, kisspeptin-10 stimulated GnRH release before and during puberty, and females were much more sensitive than males.⁴ Kisspeptin receptors also occur outside the reproductive system, including in the hippocampus, where kisspeptin-10 increased excitatory signaling between nerve cells in rat brain tissue.⁵ Its half-life in blood is only a few minutes.

What the research shows on kisspeptin-10

Kisspeptin-10 has more human research than most peptides on this site, but nearly all of it is short-term physiology rather than treatment trials.

The core finding is consistent. In several species, and by different routes, kisspeptins including kisspeptin-10 are strong stimulators of LH and FSH release.¹ Small human studies have shown that kisspeptin injections or infusions raise LH and testosterone in healthy men. In IVF research, a longer form, kisspeptin-54, has been used to trigger egg maturation as an alternative to hCG, with interest in its potential to lower the risk of ovarian hyperstimulation. Brain imaging studies in small groups of men have also reported changes in activity in regions linked to sexual and emotional processing after kisspeptin.

Several limits apply. Much of the strongest clinical work used kisspeptin-54, a longer form that lasts longer in the blood, so its results do not transfer automatically to kisspeptin-10. Most human studies involve dozens of participants or fewer and last hours to days. Responses vary by sex and, in women, by phase of the menstrual cycle. Continuous exposure can desensitize the system, so more is not always better. There are no long-term trials of kisspeptin-10 for low testosterone, infertility or low libido.

Kisspeptin also acts beyond reproduction. Its metabolic effects appear to differ by sex: in mammal studies it tended to raise metabolic activity and lower body weight in females but increase weight gain in males.⁶ Some findings raise caution. Kisspeptin-10 is a vasoconstrictor, and four weeks of infusion sped up the development of atherosclerosis in mice prone to the disease.³ That has not been studied in people.

Studied for: Reproductive axis research, Fertility research, Sexual desire research.

Kisspeptin-10 reference data

Kisspeptin-10 dosage in published research

Open this in the dosage calculator ↗

How kisspeptin-10 is used in practice

There is no approved kisspeptin product. In research settings it is given by injection or intravenous infusion under close monitoring.

Some men's health and telehealth clinics have offered kisspeptin-10 as a way to raise natural testosterone or improve libido, sometimes alongside or instead of hCG or gonadorelin. Compounding access is restricted because of FDA concerns about bulk peptides. Clinic protocols vary widely, and the very short half-life raises the question of how much a once-daily injection actually does.

Kisspeptin-10 is also sold online as a "research use only" peptide. These products are not made to pharmaceutical standards. Their identity, purity and sterility are unverified.

Kisspeptin-10 risks and side effects

In short human studies kisspeptin has been well tolerated. Reported effects include flushing, injection-site reactions and headache.

The open questions are about longer use. Repeated or continuous dosing may blunt the response rather than strengthen it. The mouse finding that kisspeptin-10 worsened atherosclerosis is a theoretical concern for people with heart disease.³ The relationship with cancer is complicated. KISS1 is generally considered a metastasis suppressor,⁷ but its role in breast cancer appears to cut both ways, with evidence for both restricting and promoting invasion.² Because kisspeptin raises sex hormones, it should be avoided with hormone-sensitive cancers. It should not be used in pregnancy.

Interactions are poorly characterized. Combining it with other drugs that act on the reproductive axis makes effects harder to predict. Grey-market products add the usual risks of wrong dose and contamination.

Reported side effects

Alternatives to kisspeptin-10

For men with confirmed low testosterone who want to preserve fertility, clinicians use hCG, clomiphene citrate (off-label) or enclomiphene, which is not FDA approved. Gonadorelin works one step further down, at the pituitary. For confirmed hypogonadism without fertility goals, FDA-approved testosterone is standard.

For low libido, approved options include bremelanotide (Vyleesi) and flibanserin (Addyi) for premenopausal women, and PDE5 inhibitors such as sildenafil and tadalafil for erectile dysfunction. For women who do not ovulate, letrozole and clomiphene are first-line treatments. In IVF, hCG and GnRH agonist triggers are the established standards.

Questions for a clinician

• What evidence applies to my situation, and at what level?
• What established alternatives should I consider first?
• What monitoring would be necessary, and how often?
• Can this be prescribed at all where I live, or only sold for research?